checkAd

     113  0 Kommentare More than 100 patients included in the human clinical trial by 31 December 2023; adapted study design meets expectations for accelerated patient recruitment - Seite 2

     

    ----------------------------------------------------------------

    aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock exchanges -

     

    About aap Implantate AG

    aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. In addition to the innovative LOQTEQ anatomical plate system, the IP-protected portfolio includes a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while internationally it primarily utilizes a broad network of distributors in around 25 countries. In the USA, the company utilizes a hybrid sales strategy through its subsidiary aap Implants Inc. Sales are conducted both via distribution agents and through partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard segment of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.

    The figures presented in this press release may be subject to technical rounding differences that do not affect the overall picture.

    Forward-looking statements

    This release may contain forward-looking statements that are based on the current expectations, assumptions and forecasts of the Executive Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situation, development or performance of the company and the estimates given here. These factors include those that aap has described in published reports. Forward-looking statements therefore only apply on the date on which they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.

    Seite 2 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    More than 100 patients included in the human clinical trial by 31 December 2023; adapted study design meets expectations for accelerated patient recruitment - Seite 2 EQS-Media / 10.01.2024 / 07:30 CET/CEST With regard to its innovative antibacterial implant technology, aap was able to successfully accelerate recruitment in the ongoing human clinical trial with the adapted study design in the course of 2023 and …

    Schreibe Deinen Kommentar

    Disclaimer